Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 214

1.

A376S in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy.

Paredes R, Puertas MC, Bannister W, Kisic M, Cozzi-Lepri A, Pou C, Bellido R, Betancor G, Bogner J, Gargalianos P, Bánhegyi D, Clotet B, Lundgren J, Menéndez-Arias L, Martinez-Picado J; EuroSIDA Study Group.

J Infect Dis. 2011 Sep 1;204(5):741-52. doi: 10.1093/infdis/jir385.

2.

N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.

Yap SH, Sheen CW, Fahey J, Zanin M, Tyssen D, Lima VD, Wynhoven B, Kuiper M, Sluis-Cremer N, Harrigan PR, Tachedjian G.

PLoS Med. 2007 Dec;4(12):e335.

3.

Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.

Bannister WP, Ruiz L, Cozzi-Lepri A, Mocroft A, Kirk O, Staszewski S, Loveday C, Karlsson A, Monforte Ad, Clotet B, Lundgren JD; EuroSIDA study group.

AIDS. 2008 Jan 30;22(3):367-76. doi: 10.1097/QAD.0b013e3282f3cc35.

PMID:
18195563
4.

Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment-naïve patients.

Hachiya A, Shimane K, Sarafianos SG, Kodama EN, Sakagami Y, Negishi F, Koizumi H, Gatanaga H, Matsuoka M, Takiguchi M, Oka S.

Antiviral Res. 2009 Jun;82(3):115-21. doi: 10.1016/j.antiviral.2009.02.189. Epub 2009 Feb 21.

5.

Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.

Bacheler L, Jeffrey S, Hanna G, D'Aquila R, Wallace L, Logue K, Cordova B, Hertogs K, Larder B, Buckery R, Baker D, Gallagher K, Scarnati H, Tritch R, Rizzo C.

J Virol. 2001 Jun;75(11):4999-5008.

6.

Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy.

Harrigan PR, Hertogs K, Verbiest W, Larder B, Yip B, Brumme ZL, Alexander C, Tilley J, O'Shaughnessy MV, Montaner JS.

Antivir Ther. 2003 Oct;8(5):395-402.

PMID:
14640386
7.

Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.

Delaugerre C, Rohban R, Simon A, Mouroux M, Tricot C, Agher R, Huraux JM, Katlama C, Calvez V.

J Med Virol. 2001 Nov;65(3):445-8.

PMID:
11596076
8.

The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI*.

Cozzi-Lepri A, Paredes, Phillips AN, Clotet B, Kjaer J, Von Wyl V, Kronborg G, Castagna A, Bogner JR, Lundgren JD; EuroSIDA in EuroCoord.

HIV Med. 2012 Jan;13(1):62-72. doi: 10.1111/j.1468-1293.2011.00943.x. Epub 2011 Aug 17.

9.

HIV-1 reverse transcriptase connection subdomain mutations involved in resistance to approved non-nucleoside inhibitors.

Menéndez-Arias L, Betancor G, Matamoros T.

Antiviral Res. 2011 Nov;92(2):139-49. doi: 10.1016/j.antiviral.2011.08.020. Epub 2011 Aug 28. Review.

PMID:
21896288
10.

Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy.

Geretti AM, Fox ZV, Booth CL, Smith CJ, Phillips AN, Johnson M, Li JF, Heneine W, Johnson JA.

J Acquir Immune Defic Syndr. 2009 Dec;52(5):569-73. doi: 10.1097/QAI.0b013e3181ba11e8.

PMID:
19779307
11.

Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis.

Ngo-Giang-Huong N, Jourdain G, Amzal B, Sang-a-gad P, Lertkoonalak R, Eiamsirikit N, Tansuphasawasdikul S, Buranawanitchakorn Y, Yutthakasemsunt N, Mekviwattanawong S, McIntosh K, Lallemant M; Program for HIV Prevention and Treatment (PHPT) study group.

PLoS One. 2011;6(11):e27427. doi: 10.1371/journal.pone.0027427. Epub 2011 Nov 23.

12.

Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children.

Cressey TR, Green H, Khoo S, Treluyer JM, Compagnucci A, Saidi Y, Lallemant M, Gibb DM, Burger DM; Paediatric European Network for Treatment of AIDS II Study Group.

Clin Infect Dis. 2008 May 15;46(10):1601-8. doi: 10.1086/587657.

13.

Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.

Gupta S, Fransen S, Paxinos EE, Stawiski E, Huang W, Petropoulos CJ.

Antimicrob Agents Chemother. 2010 May;54(5):1973-80. doi: 10.1128/AAC.00870-09. Epub 2010 Mar 1.

14.

Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen.

Marcelin AG, Descamps D, Tamalet C, Cottalorda J, Izopet J, Delaugerre C, Morand-Joubert L, Trabaud MA, Bettinger D, Rogez S, Ruffault A, Henquell C, Signori-Schmuck A, Bouvier-Alias M, Vallet S, Masquelier B, Flandre P, Calvez V; ANRS AC11 Resistance Study group.

Antivir Ther. 2012;17(1):119-23. doi: 10.3851/IMP1886.

PMID:
22267476
15.

Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort.

Tozzi V, Zaccarelli M, Narciso P, Trotta MP, Ceccherini-Silberstein F, De Longis P, D'Offizi G, Forbici F, D'Arrigo R, Boumis E, Bellagamba R, Bonfigli S, Carvelli C, Antinori A, Perno CF.

J Infect Dis. 2004 May 1;189(9):1688-95. Epub 2004 Apr 13.

16.

Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.

Gatanaga H, Ode H, Hachiya A, Hayashida T, Sato H, Oka S.

Antimicrob Agents Chemother. 2010 Apr;54(4):1596-602. doi: 10.1128/AAC.01480-09. Epub 2010 Feb 1.

17.

Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.

Hachiya A, Kodama EN, Sarafianos SG, Schuckmann MM, Sakagami Y, Matsuoka M, Takiguchi M, Gatanaga H, Oka S.

J Virol. 2008 Apr;82(7):3261-70. doi: 10.1128/JVI.01154-07. Epub 2008 Jan 23.

18.

Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with nevirapine, efavirenz or abacavir.

Ochoa de Echagüen A, Arnedo M, Xercavins M, Martinez E, Rosón B, Ribera E, Domingo P, González A, Riera M, Llibre JM, Gatell JM, Dalmau D; Nevirapine, Efavirenz and Abacavir (NEFA) Resistance Substudy Team.

AIDS. 2005 Sep 2;19(13):1385-91.

PMID:
16103769
19.

Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088).

Vray M, Meynard JL, Dalban C, Morand-Joubert L, Clavel F, Brun-Vézinet F, Peytavin G, Costagliola D, Girard PM; Narval Trial Group.

Antivir Ther. 2003 Oct;8(5):427-34.

PMID:
14640390
20.

Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine.

Alcaro S, Alteri C, Artese A, Ceccherini-Silberstein F, Costa G, Ortuso F, Bertoli A, Forbici F, Santoro MM, Parrotta L, Flandre P, Masquelier B, Descamps D, Calvez V, Marcelin AG, Perno CF, Sing T, Svicher V.

ChemMedChem. 2011 Dec 9;6(12):2203-13. doi: 10.1002/cmdc.201100362. Epub 2011 Sep 27.

PMID:
21953939
Items per page

Supplemental Content

Write to the Help Desk